Brought to you by 
Alnylam, Genzyme expand their RNAi therapies alliance, Genzyme invests $700mm; deal restructured
27 May 2021
Executive Summary
Vastly expanding on and replacing a 2012 alliance surrounding RNAi therapies for transthyretin-mediated amyloidosis (ATTR), Alnylam Pharmaceuticals Inc. and Sanofi’s Genzyme Corp. signed a new agreement for the development of RNAi treatments for genetic diseases. Genzyme gains additional rights and becomes a major Alnylam shareholder.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam, Genzyme expand their RNAi therapies alliance, Genzyme invests $700mm; deal restructured
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice